List view / Grid view
Despite hundreds of off-the-shelf treatments, cancer remains the second leading cause of death globally.
T cell-based therapies have shown promise as new treatment options for various cancers.
A detailed analysis of the body's immune response to COVID-19 has revealed that it can recognise SARS-CoV-2 in many ways, meaning vaccines can be used to stop the spread of the virus.
A new kind of dendritic cell has been discovered by researchers and could play a role presenting antigens to other immune cells during respiratory virus infections.
By culturing blood cells with mesenchymal stromal cells (MSCs), researchers induced the production of cells with the same functionality as Tregs.
Researchers have unravelled the viral transcriptome and translatome of the herpes simplex virus (HSV-1) to aid disease research and immunotherapy.
Exploring how therapies with multi-faceted approaches could improve options for treatment-refractory cancers, like pancreatic and triple-negative breast cancer.
Scientists from Singapore have argued that T-cell immunotherapy can be used to combat a range of infectious diseases, including COVID-19.
Researchers have created a new kind of immunotherapy using the interleukin-27 (IL-27) cytokine to effectively combat tumours in vitro and in vivo.
A new CAR T-cell therapy has been created by researchers which targets three proteins on leukaemia cells and has shown success in pre-clinical trials.
A new study has shown that the role of T cell-suppressing dendritic cells can be reversed in mice, indicating that immunotherapies could be improved with this method.
Grifols will leverage their resources to develop and test convalescent plasma-derived COVID-19 therapeutics in partnership with the FDA and BARDA.
By removing two kinds of macrophages in mice, researchers showed that ovarian tumours in mice were reduced in size and stopped spreading.
The University of Georgia and CEL-SCI Corporation have partnered to develop an immunotherapy to combat the COVID-19 coronavirus using the Ligand Antigen Epitope Presentation System (LEAPS) technology.
Chimeric antigen receptor (CAR) T-cell therapies have produced encouraging clinical outcomes, demonstrating their therapeutic potential in mitigating tumour development. However, another form of T-cell immunotherapy based on T-cell receptors (TCR) has also shown great potential in this field. Here, Nikki Withers speaks to Miguel Forte who elaborates on the process…
